Reinhard Hohlfeld
#116,030
Most Influential Person Now
Researcher
Reinhard Hohlfeld's AcademicInfluence.com Rankings
Reinhard Hohlfeldphysics Degrees
Physics
#4368
World Rank
#6017
Historical Rank
Particle Physics
#182
World Rank
#195
Historical Rank

Download Badge
Physics
Why Is Reinhard Hohlfeld Influential?
(Suggest an Edit or Addition)Reinhard Hohlfeld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. (2010) (2329)
- Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? (1999) (1008)
- Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction (2000) (940)
- Polymyositis and dermatomyositis (2003) (718)
- Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice (2017) (556)
- MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. (2009) (545)
- Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. (2006) (498)
- BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma (2005) (445)
- BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? (2002) (402)
- Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. (1997) (397)
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
- Neurofascin as a novel target for autoantibody-mediated axonal injury (2007) (382)
- Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. (2004) (354)
- Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. (2000) (311)
- Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica (2008) (308)
- Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis (2011) (286)
- B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation (2006) (279)
- The immunobiology of muscle. (1994) (276)
- Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases (2003) (272)
- Mechanisms of action of glatiramer acetate in multiple sclerosis (2001) (269)
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab (2011) (265)
- Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. (2002) (264)
- Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis (2008) (262)
- Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines (2004) (254)
- B cells and antibodies in multiple sclerosis pathogenesis and therapy (2012) (245)
- Multiple sclerosis (1999) (240)
- Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. (1996) (240)
- γ-secretase directly sheds the survival receptor BCMA from plasma cells (2015) (231)
- Autoimmune human T lymphocytes specific for acetylcholine receptor (1984) (224)
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis (2005) (218)
- Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations (2008) (218)
- A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS (2002) (216)
- Neurofascin as a target for autoantibodies in peripheral neuropathies (2012) (213)
- Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica (2007) (211)
- Multiple sclerosis: T-cell receptor expression in distinct brain regions. (2007) (205)
- Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals (2009) (203)
- Myasthenia gravis (1983) (201)
- Immunobiology of muscle: advances in understanding an immunological microenvironment. (2005) (192)
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
- Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis (2008) (188)
- Human myoblasts as antigen presenting cells (1991) (180)
- NMO-IgG in the diagnosis of neuromyelitis optica (2007) (178)
- Neuro-immune crosstalk in CNS diseases (2009) (175)
- Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis (2016) (175)
- The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis (2000) (167)
- Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. (2008) (164)
- Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. (2000) (164)
- Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. (1999) (164)
- The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research (2016) (161)
- Histopathology and clinical course of MOG-antibody-associated encephalomyelitis (2015) (153)
- Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society (2016) (153)
- Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. (2004) (150)
- The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets (2016) (149)
- Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS (2011) (146)
- The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis (2006) (142)
- T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells (1995) (141)
- Polymyositis Mediated by T Lymphocytes That Express the γ/δ Receptor (1991) (138)
- Corticosteroids for myasthenia gravis. (2005) (137)
- Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. (1997) (136)
- Glatiramer Acetate in the Treatment of Multiple Sclerosis (2011) (130)
- From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. (2014) (130)
- Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation (2016) (127)
- Extracellular Matrix in Multiple Sclerosis Lesions: Fibrillar Collagens, Biglycan and Decorin are Upregulated and Associated with Infiltrating Immune Cells (2010) (127)
- Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action (2005) (126)
- Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins (2016) (126)
- Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin (2011) (124)
- Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. (2002) (123)
- HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS (1986) (120)
- Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. (2003) (120)
- Features of Human CD3+CD20+ T Cells (2016) (119)
- Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. (1993) (119)
- CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions (2007) (119)
- Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. (2001) (117)
- Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. (2005) (116)
- Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases (2013) (116)
- Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration (2012) (115)
- Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. (2012) (114)
- The emerging role of microRNAs in multiple sclerosis (2011) (114)
- Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis (2003) (114)
- Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin (1996) (114)
- The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls (2001) (114)
- Long-term effects of fingolimod in multiple sclerosis (2015) (113)
- Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein (2018) (113)
- Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. (1994) (113)
- Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravis (1988) (110)
- Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. (2004) (109)
- Immunological update on multiple sclerosis (2001) (109)
- Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G (2000) (109)
- Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives (2017) (108)
- Dual role of inflammation in CNS disease (2007) (107)
- Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis. (1994) (106)
- Induction of HLA-DR expression on human myoblasts with interferon-gamma. (1990) (106)
- Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. (1998) (104)
- Neutralizing antibodies and efficacy of interferon β-1a (2005) (102)
- Myasthenia gravis: Reactivation of clinical disease and of automimmune factors after discontinuation of long‐term azathioprine (1985) (101)
- Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies (1991) (101)
- Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. (2012) (98)
- Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. (1987) (95)
- The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. (2003) (95)
- Therapies for multiple sclerosis: translational achievements and outstanding needs. (2013) (94)
- Multiple sclerosis. Immunomodulatory effects of human astrocytes on T cells. (1994) (94)
- Quantification of Perfusion and Permeability in Multiple Sclerosis: Dynamic Contrast-Enhanced MRI in 3D at 3T (2012) (93)
- The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity (2015) (91)
- Immortalization of human T cells by Herpesvirus saimiri. (1995) (91)
- THYMIC MYOGENESIS, T‐LYMPHOCYTES AND THE PATHOGENESIS OF MYASTHENIA GRAVIS * (1981) (91)
- Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. (2001) (89)
- Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor‐α by HLA‐DR2+ T cells (1995) (88)
- Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor (1997) (88)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis (2016) (85)
- The role of neurotrophins in muscle under physiological and pathological conditions (2006) (83)
- Cellular immune mechanisms in inflammatory myopathies. (1997) (83)
- Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. (1992) (83)
- T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors. (2003) (81)
- The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis (1995) (80)
- De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate (2011) (80)
- Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid (2015) (79)
- Multiple sclerosis therapeutics (2009) (79)
- Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis (2008) (78)
- Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy (2014) (78)
- Risks and risk management in modern multiple sclerosis immunotherapeutic treatment (2019) (78)
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) (76)
- Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis (2001) (76)
- Role of B Cells in Multiple Sclerosis and Related Disorders (2020) (73)
- Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. (2004) (73)
- Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
- Transformation of human T-cell clones by Herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells. (1993) (72)
- Reconstitution of paired T cell receptor α- and β-chains from microdissected single cells of human inflammatory tissues (2006) (71)
- Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders (2011) (70)
- Mechanism of action of glatiramer acetate in treatment of multiple sclerosis (2007) (69)
- Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B–cell response (2005) (69)
- PML risk stratification using anti-JCV antibody index and L-selectin (2016) (67)
- Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury (2010) (67)
- Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. (2014) (67)
- Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. (2007) (67)
- Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis (2011) (65)
- Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis (2013) (65)
- Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. (1997) (65)
- Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF (2015) (64)
- Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration (2016) (64)
- The ups and downs of multiple sclerosis therapeutics (2001) (63)
- Myasthenia gravis (1986) (63)
- Multiple sclerosis: prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity (1996) (63)
- Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. (2019) (63)
- T-cell heterogeneity in muscle lesions of inclusion body myositis (1998) (63)
- Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. (1988) (62)
- Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. (2007) (62)
- Fingolimod induces neuroprotective factors in human astrocytes (2015) (62)
- Autoaggressive myocytotoxic T lymphocytes expressing an unusual gamma/delta T cell receptor (1992) (61)
- Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients (2002) (61)
- Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab (2009) (61)
- Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. (1985) (60)
- Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides (2012) (59)
- Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. (1997) (57)
- Bidirectional growth of the E. coli chromosome. (1973) (57)
- ["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. (2010) (56)
- Humoral autoimmunity in multiple sclerosis (2011) (56)
- Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy (2005) (56)
- BK virus encephalitis in an immunocompetent patient. (1996) (55)
- Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. (2007) (53)
- Neurological autoimmune disease and the trimolecular complex of T‐lymphocytes (1989) (49)
- The role of the thymus in myasthenia gravis. (1994) (49)
- Target Specificity of an Autoreactive Pathogenic Human γδ-T Cell Receptor in Myositis* (2012) (48)
- Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology (2016) (48)
- The immunopathogenesis of myasthenia gravis. (2008) (47)
- Drug Insight: using monoclonal antibodies to treat multiple sclerosis (2005) (46)
- Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein‐specific T cell clone (1993) (46)
- Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis (2002) (46)
- Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis? (2008) (45)
- Molecular mimicry in multiple sclerosis. (2003) (44)
- Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. (1990) (43)
- Myasthenia gravis: prototype of the antireceptor autoimmune diseases. (1990) (43)
- Expression and Function of Glial Cell Line-Derived Neurotrophic Factor Family Ligands and Their Receptors on Human Immune Cells1 (2005) (43)
- First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine (2021) (42)
- Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations (2015) (42)
- DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis (2019) (41)
- αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features (2015) (41)
- Molecular pathogenesis of neuroinflammation (2003) (41)
- Inclusion Body Myositis (2006) (41)
- The recognition, diagnosis and management of cerebral vasculitis: a European survey (2002) (41)
- An Autoreactive γδ TCR Derived from a Polymyositis Lesion1 (2002) (40)
- T-cell autoimmunity in multiple sclerosis. (1995) (39)
- Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study (2004) (37)
- Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study (2019) (37)
- Autoimmune rat T lymphocytes monospecific for acetylcholine receptors: purification and fine specificity. (1981) (37)
- Assessment of Potential Cardiotoxic Side Effects of Mitoxantrone in Patients with Multiple Sclerosis (2005) (35)
- Multiple Sclerosis: Clinical Challenges and Controversies (1997) (35)
- Reflections on the “intrathymic pathogenesis” of myasthenia gravis (2008) (34)
- Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis (2018) (34)
- Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination (2014) (34)
- Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement (2017) (34)
- Cellular mechanisms in inflammatory myopathies. (1993) (33)
- Review: Progress in the treatment of myasthenia gravis (2008) (33)
- [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]. (2000) (32)
- Identification of circulating MOG-specific B cells in patients with MOG antibodies (2019) (31)
- Multiple sclerosis: Human model for EAE? (2009) (31)
- Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. (1998) (31)
- Immunopathogenesis of multiple sclerosis: MBP and beyond (2002) (31)
- Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. (1991) (30)
- Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis (2012) (30)
- Effector mechanisms in myasthenia gravis: End‐plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules (1986) (30)
- Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy (2017) (30)
- Myasthenia gravis (1991) (30)
- Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity (2020) (29)
- Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod (2014) (29)
- Muscle-derived positive and negative regulators of the immune response (2005) (28)
- Experimental myasthenia: Lack of correlation between the autoantibody titer and the reduction of acetylcholine‐controlled ionic channels measured at functioning endplates (1983) (28)
- Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. (2004) (28)
- Multiple sclerosis and the TNFRSF1A R92Q mutation (2008) (28)
- Multiple Sclerosis: A Comprehensive Text (2008) (28)
- Multiple sclerosis–like lesions and type I interferon signature in a patient with RVCL (2014) (27)
- Thymoma-associated myasthenia gravis. Transplantation of thymoma and extrathymomal thymic tissue into SCID mice. (1996) (27)
- Prospects of Transcript Profiling for mRNAs and MicroRNAs Using Formalin‐Fixed and Paraffin‐Embedded Dissected Autoptic Multiple Sclerosis Lesions (2012) (27)
- Future clinical challenges in multiple sclerosis (2011) (26)
- Twin study reveals non-heritable immune perturbations in multiple sclerosis (2022) (26)
- Expression of 65‐kd heat shock proteins in the inflammatory myopathies (1992) (25)
- Immune signatures of prodromal multiple sclerosis in monozygotic twins (2020) (24)
- Different aspects of cytokines in the immunopathology of multiple scleroosis (1995) (24)
- Molecular pathogenesis of neuroinflammation. (2003) (24)
- Therapy of Myasthenia Gravis and Myasthenic Syndromes (2003) (23)
- Expression and Function of Glial Cell Line-Derived Neurotrophic Factor Family Ligands and Their Receptors on Human Immune Cells (2005) (23)
- Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis (2020) (22)
- Growth transformation of antigen-specific T cell lines from rhesus monkeys by herpesvirus saimiri. (1997) (22)
- Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course (2022) (21)
- Myasthenia gravis: Discontinuation of long‐term azathioprine (1988) (21)
- Does inflammation stimulate remyelination? (2007) (20)
- Inhibitors of tumor necrosis factor-α: Promising agents for the treatment of multiple sclerosis? (1996) (19)
- T-lymphocytes in experimental autoimmune myasthenia gravis Isolation of T-helper cell lines (1982) (19)
- T cell transformation with Herpesvirus saimiri: a tool for neuroimmunological research (2000) (19)
- [Immunogenetics of myasthenia gravis. Significance of HLA-, complement and Cm gene systems for clinical and immunologic parameters]. (2008) (19)
- Immunologic factors in primary progressive multiple sclerosis (2004) (19)
- Therapeutic Approaches in Multiple Sclerosis (2012) (19)
- HLA expression in myoblasts (1991) (18)
- Novel approaches for identifying target antigens of autoreactive human B and T cells (2009) (18)
- Basic principles of immunotherapy for neurologic diseases. (2003) (18)
- B- and T-cell responses in multiple sclerosis: Novel approaches offer new insights (2008) (18)
- Communication of CD8+ T cells with mononuclear phagocytes in multiple sclerosis (2019) (17)
- Multiple sclerosis: TNFRSF1A, TRAPS and multiple sclerosis (2009) (17)
- BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology (2008) (17)
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Suggests Normal Perfusion in Normal-Appearing White Matter in Multiple Sclerosis (2016) (17)
- Gut Microbiota in Multiple Sclerosis: A Bioreactor Driving Brain Autoimmunity (2016) (17)
- TNFRSF1A R92Q MUTATION IN ASSOCIATION WITH A MULTIPLE SCLEROSIS–LIKE DEMYELINATING SYNDROME (2008) (16)
- Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status (2007) (16)
- Ocrelizumab in multiple sclerosis: markers and mechanisms (2017) (16)
- Acetylcholine Receptor‐Specific Human T‐Lymphocyte Lines a (1987) (16)
- Biomarkers in Multiple Sclerosis (2006) (16)
- Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. (1997) (15)
- Differential aspects of cytokines in the immunopathology of multiple sclerosis. (1995) (15)
- The role of the gut microbiota in multiple sclerosis (2022) (15)
- Features of MOG required for recognition by patients with MOG antibody-associated disorders. (2021) (15)
- Autoaggressive Myocytotoxic T Lymphocytes Expressing an Unusual 7 / ~ T Cell Receptor (2003) (15)
- Managing Risks with Immune Therapies in Multiple Sclerosis (2019) (15)
- Therapeutic strategies in multiple sclerosis. I. Immunotherapy. (1999) (15)
- Abundant glutamic acid decarboxylase (GAD)‐reactive B cells in gad‐antibody–associated neurological disorders (2019) (15)
- T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis. (2015) (15)
- Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. (2009) (15)
- Immunology of MS (1998) (15)
- Update on sporadic inclusion body myositis. (2011) (14)
- Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis (2016) (14)
- [Revision of McDonald's new diagnostic criteria for multiple sclerosis]. (2006) (14)
- Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis (2021) (14)
- [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. (2005) (14)
- Revisiting the immunopathogenesis of the inflammatory myopathies (2007) (14)
- Myelin failure in multiple sclerosis: Breaking the spell of Notch (2002) (14)
- Myogenesis in thymic transplants in the severe combined immunodeficient mouse model of myasthenia gravis. Differentiation of thymic myoid cells into striated muscle cells. (1994) (13)
- Cytotoxic T cells go awry in inclusion body myositis. (2016) (13)
- Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (13)
- Biologically stressed muscle fibers in sporadic IBM (2000) (13)
- Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) (2012) (13)
- Strategies for the modulation of neuroimmunological disease at the level of autoreactive T-lymphocytes (1985) (13)
- Immunology of Neuromuscular Disease (1994) (13)
- Diagnostic criteria for polymyositis and dermatomyositis (2003) (13)
- [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. (2011) (13)
- Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 (2010) (13)
- The use of intravenous immunoglobulins in the treatment of neuromuscular disorders (1996) (12)
- Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. (2014) (12)
- An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis (2020) (12)
- Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem (2013) (11)
- Type III Systemic Allergic Reaction to Natalizumab. Authors' reply (2008) (11)
- An autoreactive gamma delta TCR derived from a polymyositis lesion. (2002) (11)
- Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal (2021) (11)
- Necrotizing myopathy in SJL mice. (1988) (11)
- Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit ( immunoregulation / autoimmune disease / immunotherapy ) (11)
- The role of gamma-delta T lymphocytes in inflammatory muscle disease. (1992) (11)
- The Glycosylation Site of Myelin Oligodendrocyte Glycoprotein Affects Autoantibody Recognition in a Large Proportion of Patients (2019) (11)
- Polymyositis and dermatomyositis. (2003) (11)
- Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? (1996) (11)
- Gardener's mydriasis (1992) (11)
- Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. (2016) (11)
- Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group” (2013) (11)
- Neuro-immune crosstalk in CNS diseases. (2010) (10)
- Analysis of immunoglobulin and T cell receptor gene rearrangements in the thymus of myasthenia gravis patients (1989) (10)
- Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies (2007) (10)
- Non-specific alterations of craniocervical venous drainage in multiple sclerosis revealed by cardiac-gated phase-contrast MRI (2012) (10)
- [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. (2016) (10)
- T Cell Receptor Repertoire in Polymyositis : Clonal Expansion of Autoaggressive CD 8 + T Cells (2003) (9)
- [Open use of natalizumab. Neutralising antibodies and clinical data]. (2008) (9)
- Antigen recognition properties of a Vγ1.3Vδ2-T-cell receptor from a rare variant of polymyositis (2004) (9)
- Drug-induced Sweet’s syndrome after mitoxantrone therapy in a patient with multiple sclerosis (2011) (9)
- Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis (2012) (8)
- Thirty-one episodes of myelitis and optic neuritis in a woman with neuromyelitis optica and systemic lupus erythematosus. (2010) (8)
- Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis (2019) (8)
- Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
- [Pregnancy and immunomodulatory therapy in multiple sclerosis patients]. (2006) (8)
- T Cell–Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity (2017) (8)
- Multiple Sclerosis Therapeutics, 3rd ed (2007) (7)
- Epstein-Barr virus-transformed B cells can present acetylcholine receptor to autologous autoreactive T cells. (1986) (7)
- Molecular oracles for multiple sclerosis therapy (2010) (7)
- How promising is hematopoetic stem cell transplantation in multiple sclerosis? (2002) (7)
- B-cells as therapeutic targets in neuro-inflammatory diseases. (2017) (7)
- The CSF JCV antibody index for diagnosis of natalizumab-associated PML (2014) (7)
- Cytokine networks in multiple sclerosis (1995) (7)
- Assessing the quality of life of patients with multiple sclerosis (1997) (7)
- [Multiple sclerosis and retroviruses]. (2009) (7)
- Multiple Sklerose Chlamydien-Hypothese in der Diskussion (2001) (7)
- [Immunotherapies for multiple sclerosis : review and update]. (2015) (7)
- Myositis Diagnosis and Management (2002) (6)
- Neuromuscular transmission in experimental autoimmune myasthenia gravis (EAMG) (1981) (6)
- Anti-titin antibodies are not associated with a specific thymoma histology (2003) (6)
- Antiglutamatergic therapy for multiple sclerosis? (2016) (6)
- CHAPTER 16 – Principles of Therapeutic Approaches to Autoimmunity (1992) (6)
- Ion channels boost axonal injury in multiple sclerosis (2012) (6)
- [Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis]. (2002) (6)
- Hunting (auto)immune T cells in neuroimmunological diseases. (2003) (6)
- Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (6)
- ['Fatigue' in multiple sclerosis]. (1999) (5)
- Expression and role of novel B7 family members in human muscle: implications for the pathogenesis of inflammatory myopathies (2004) (5)
- [Update: treatment of multiple sclerosis]. (2009) (5)
- [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system]. (2011) (5)
- Plasma lipidomics of monozygotic twins discordant for multiple sclerosis (2020) (5)
- The prospects for neuroprotection in MS. (2003) (5)
- [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects]. (1996) (5)
- Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation (2013) (5)
- [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies]. (2002) (4)
- Beneficial brain autoimmunity? (2010) (4)
- CD20+ T Cells as Pathogenic Players and Therapeutic Targets in MS (2021) (4)
- Multiple sclerosis (2016) (4)
- Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair (2022) (4)
- [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]. (1999) (4)
- [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. (2011) (4)
- Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies (2002) (4)
- [Multiple sclerosis. Chlamydia hypothesis in debate]. (2001) (4)
- Permanent Lines of T Lymphocytes Specific for Acetylcholine Receptors: A Clonal Approach to Study the Pathogenesis of Myasthenia Gravis (1984) (4)
- Multiple sclerosis: Cladribine—a contentious therapeutic contender for MS (2011) (4)
- A bird's-eye view of T cells during natalizumab therapy (2013) (4)
- Myasthenia gravis: selective enrichment of antiacetylcholine receptor antibody production in untransformed human B cell cultures (1999) (3)
- Intrathecal immune response against Chlamydia pneumoniae in multiple sclerosis (2001) (3)
- Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal (2021) (3)
- Zero tolerance (to acetylcholine receptor) and ways to overcome it (2010) (3)
- [Multiple sclerosis and microbiota. From genome to metagenome?]. (2015) (3)
- [Interferon-beta in treatment of relapsing multiple sclerosis]. (1994) (3)
- Prejunctional effects of anticholinesterase drugs at the endplate (1981) (3)
- Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972) (2020) (3)
- T-cell mediated autoimmunity: molecular interactions and therapeutic implications. (1990) (3)
- β-Amyloid: Enemy or Remedy? (2012) (3)
- Muscle ® bres and cultured muscle cells express the B 7 . 1 / 2-related inducible co-stimulatory molecule , ICOSL : implications for the pathogenesis of in ̄ ammatory myopathies (2003) (3)
- [Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy]. (2006) (3)
- Alemtuzumab and Multiple Sclerosis: Another Note of Caution. (2016) (3)
- The prospects for neuroprotection in MS. (Editorial) (2003) (3)
- Chapter 53 – Multiple Sclerosis (2003) (3)
- Neurotrophic factors protect myelin from attack. (2003) (3)
- Immune responses in muscle (1992) (3)
- [2012: Update on diagnosis and treatment of multiple sclerosis]. (2012) (3)
- [Current aspects of therapy conversion for multiple sclerosis]. (2015) (3)
- [Blocking adhesion molecules with natalizumab in multiple sclerosis]. (2005) (3)
- Extracellular matrix in multiple sclerosis lesions: Induction of fibrillar collagens, biglycan, and decorin in association with infiltrating immune cells (2008) (2)
- Progress in understanding inflammatory and autoimmune diseases of the central nervous system (2009) (2)
- [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. (2004) (2)
- [Immunogenetics of myasthenia gravis]. (1983) (2)
- Physiochemical and immunological properties of acetylcholine receptors from human muscle (1984) (2)
- Review T-Cell-Mediated Autoimmunity Novel Techniques to Characterize Autoreactive T-Cell Receptors (2003) (2)
- [Multiple sclerosis: updates on pathogenesis and treatment: report from the 9th MS Symposium held by the German Multiple Sclerosis Society]. (2011) (2)
- Cannabinoids in multiple sclerosis. Opportunity or threat (2004) (2)
- Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. (1993) (2)
- Multiple sclerosis therapy: new agents carry new risks (2006) (2)
- Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis (2010) (2)
- TNFRSF1A in multiple sclerosis (2013) (2)
- [Interferon therapy of multiple sclerosis. A question of the correct dose?]. (2001) (2)
- Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy. (2004) (2)
- Natalizumab-induced PML: can the beast be tamed? (2013) (2)
- Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum. (2019) (2)
- [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy]. (2009) (2)
- Myasthenia gravis (1999) (2)
- [Suspected multiple sclerosis]. (2006) (2)
- Regulatory T cells in myositis — Good Samaritans at the site of inflammation? (2010) (2)
- Faculty Opinions recommendation of A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. (2010) (2)
- The basis of immunotherapy in neurological disease (2002) (2)
- [Diagnosis and treatment of multiple sclerosis. Update, 2003]. (2003) (2)
- Type III Systemic Allergic Reaction to Natalizumab—Reply (2008) (2)
- Neurodegeneration, neuroprotection, glial cells, and myelin in multiple sclerosis (2007) (2)
- The Role of Cytotoxic Effector Molecules and Cytokines in Inflammatory Myopathies (2002) (2)
- [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure]. (1997) (2)
- [Interferon therapy of multiple sclerosis. Synopsis of various dosage forms]. (2004) (2)
- Concurrent TNFRSF1A R92Q and pyrin E230K mutations in a child with multiple sclerosis (2010) (2)
- Patient-to-patient transmission of natalizumab-associated PML? (2017) (2)
- Cytokine-Based Therapeutics for Intrinsic CNS Disease Processes (2005) (1)
- Differences in Antigen Expression on Normal Thymocytes and on Cells Derived from Hyperplastic Thymi and Thymoma of Myasthenia Gravis Patients (1984) (1)
- Influence of ultraviolet radiation and diminished-function melanocortin 1 receptor variants on multiple sclerosis disease severity in two large multicenter cohort studies (2019) (1)
- Multiple Sclerosis: New Immunobiologics (2007) (1)
- What T-cell receptors can tell us about neurologic disease (2012) (1)
- A clue for the enigmatic etiology? (2000) (1)
- Aktuelle Therapie der multiplen Sklerose: Mitoxantron [Current therapy of multiple sclerosis: mitoxantrone] (1994) (1)
- BAFF production in human brain by astrocytes: the central nervous system as a B cell fostering environment (2004) (1)
- Myasthenia gravis: new therapeutic strategies. (1988) (1)
- [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. (1991) (1)
- [Copolymer 1 in therapy of multiple sclerosis]. (1995) (1)
- Myelin oligodendrocyte glycoprotein specific autoantibodies in adult patients with different inflammatory diseases of the CNS (2014) (1)
- Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy (2019) (1)
- Effects of fingolimod treatment on astrocyte functions (2013) (1)
- Multiple sclerosis (PP-038) (2010) (1)
- Multiple sclerosis meets systems immunology (2021) (1)
- Autoimmune diseases of muscle (1994) (1)
- Intravenous immunoglobulins in MS: a panacea lacking approval? (2005) (1)
- [Current therapy of multiple sclerosis. Are there indications for plasmapheresis?]. (1992) (1)
- Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis (P01.199) (2013) (1)
- Fasciculations in lower motor neuron disease (1983) (1)
- Disease course during pregnancy in patients with highly active multiple sclerosis (2016) (1)
- [Multiple sclerosis: between wish and reality]. (2005) (1)
- Multiple Sklerose – Revision der neuen McDonald-Diagnosekriterien (2006) (1)
- Modulating microbiota: friend or foe? (2015) (1)
- The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. (2000) (1)
- Thymus in Thymoma-Associated Myasthenia Gravis (1997) (1)
- ISNI 2012 Abstracts (2012) (1)
- Antigen recognition properties of a Vgamma1.3Vdelta2-T-cell receptor from a rare variant of polymyositis. (2004) (1)
- Stimulation of Autoimmune Helper T Lymphocytes from Patients with Myasthenia Gravis with Synthetic Peptides of the Acetylcholine Receptor Alpha Subunit a (1988) (1)
- Interferon-beta 1a in der Therapie der schubförmigen multiplen Sklerose (1997) (1)
- Pathogenic mechanisms of human autoantibodies against myelin oligodendrocyte glycoprotein (2017) (1)
- [New approaches for the treatment of neurological diseases]. (2013) (1)
- Modulation of sphingosine 1-phosphate signaling in neurologic disease (2011) (1)
- Immunological basis for the therapy of multiple sclerosis. (1999) (1)
- DNA Methylation Signatures of a Large Cohort Monozygotic Twins Clinically Discordant for Multiple Sclerosis (2018) (1)
- A practicable method for the analysis of T lymphocyte subsets in CSF lymphopleocytosis (1983) (1)
- [Multiple sclerosis: potential therapeutic options and update of ongoing studies]. (2004) (1)
- [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. (2007) (1)
- In Vitro Propagation of Acetylcholine Receptor‐Specific Human T Lymphocytes with Autologous Epstein‐Barr Virus‐Transformed B Lymphocytes a (1987) (0)
- Rapid Communication Induction ofHLA-DRExpression onHuman Myoblasts with Interferon-Gamma (1990) (0)
- [Current therapy of multiple sclerosis: "T-cell vaccination"]. (1994) (0)
- ADAM10 releases the immunoregulator soluble TACI — A novel biomarker for B-cell pathologies (2014) (0)
- Target specificity of an autoreactive human -T cell receptor in myositis* (2012) (0)
- THE ROLE OF FIBROBLAST GROWTH FACTOR-9 IN CHRONICALLY DEMYELINATED MULTIPLE SCLEROSIS LESIONS (2011) (0)
- New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits (2017) (0)
- Expression of HLA-G in inflammatory muscle diseases and myoblast culture (1998) (0)
- [Current therapy of multiple sclerosis: are there indications for intravenous immunoglobulins?]. (1995) (0)
- Immunotherapeutic Strategies for Multiple Sclerosis (2001) (0)
- Finding cures for neurological diseases (2022) (0)
- IgG synthesis within multiple sclerosis lesions correlates with local BAFF production (2008) (0)
- First results of a prospective cohort study in clinically isolated syndromes and early multiple sclerosis of the German Competence Network Multiple Sclerosis (2015) (0)
- Chapter 19 Future Therapies (2003) (0)
- Akute demyelinisierende Enzephalomyelitis (ADEM) (1999) (0)
- Anti-MOG autoantibodies in children with acute demyelination: Comparison of assays and longitudinal analysis (2011) (0)
- [Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)]. (1996) (0)
- Fifth Meeting of the European Neurological Society (2004) (0)
- Intracellular production of brain-derived neurotropbic factor (BDNF) in T-cells of healthy controls, untreated MS patients and interferon-beta treated MS patients before and after stimulation with PMA/ionomycin or interferon-beta (2004) (0)
- Oral Presentations (2004) (0)
- Quantification of cerebral hemodynamics in patients with multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T (2011) (0)
- [Neuroinflammatory diseases with a focus on multiple sclerosis - an overview]. (2013) (0)
- Inflammatory Lesions (CD80) and B7.2 (CD86) In Vitro and in Costimulatory Molecule Distinct from B7.1 Human Muscle Cells Express a Functional (1998) (0)
- Retromer Sorting A Pathogenic Pathway in Late-Onset Alzheimer Disease (2008) (0)
- MicroRNA profiles of different types of MS lesions (2008) (0)
- Expression of a B7-family protein distinct from B7.1 and B7.2 (1998) (0)
- Gamma-delta T cells (WS-094) Chairpersons: Yoshimasa Tanaka, Marc Bonneville (2010) (0)
- [B lymphocytes: a new "target" in treatment for multiple sclerosis]. (2009) (0)
- [Corticosteroid therapy in multiple sclerosis. Comment on the letter by M. Haupts et al]. (1994) (0)
- IMMUNOLOGICAL AND INFLAMMATORY DISORDERS OF THE CENTRAL NERVOUS SYSTEM. (1999) (0)
- Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid (2015) (0)
- Antigen-dependent HLA-DR-restricted lysis of human astrocytes by CD4+ T-cell lines specific for myelin-basic protein (MBP) (1991) (0)
- The effect of a combined mitoxantrone and methylprednisolone therapy in primary compared to secondary progressive multiple sclerosis – an interim analysis after five years (2004) (0)
- [Tumor necrosis factor and multiple sclerosis]. (1992) (0)
- [Multiple sclerosis and retroviruses: new findings]. (1990) (0)
- Stimulation of autoimmune helper T-lymphocytes from myasthenia gravis patients with synthetic peptides of the acetylcholine receptor alpha subunit (1987) (0)
- Germany (2005) (0)
- An animal model for paraneoplastic encephalitis (2004) (0)
- Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis – an interim analysis after five years (2004) (0)
- CURING MS: How science is solving the mysteries of multiple sclerosis By Howard L. Weiner 2004. New York: Crown Publishers. Price $24.95 ISBN 0-609-60900-9 (2005) (0)
- A reliable method for immunocytochemical characterization of CSF cells (1987) (0)
- [Progress of therapy in patients with multiple sclerosis]. (2010) (0)
- Stop inflammation and you stop neurodegeneration in MS – Commentary (2017) (0)
- Multiple sclerosis (WS-038) Chairpersons: Jyun-ichi Kira, Richard Ransohoff (2010) (0)
- Antigen-specific tolerance induction by transcriptional targeting of dendritic cells with a novel lentiviral vector (2008) (0)
- Gene expression analysis in formalin fixed and paraffin embedded (FFPE) vs. frozen samples from multiple sclerosis patients and controls (2008) (0)
- Interferon beta-1b in multiple sclerosis - A seminar-in-print - Questions and answers (1996) (0)
- Mesenchymal stem cells for multiple sclerosis: hype or hope? (2021) (0)
- [Status and perspectives in the therapy of multiple sclerosis. A. Multiple sclerosis; the facts]. (1997) (0)
- B lineage cells in inflammatory central nervous system - Reply (2006) (0)
- [Therapy of multiple sclerosis]. (1999) (0)
- Toward identification of personalized immunological profiles in multiple sclerosis. (2022) (0)
- Chapter 8. Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis (2008) (0)
- Faculty Opinions recommendation of Transgenic labeling of the corticospinal tract for monitoring axonal responses to spinal cord injury. (2006) (0)
- Anti-nicotinic receptor autoimmunity in myasthenia gravis. Establishment of specific T-helper cell lines and identification of sensitizing epitopes on the alpha-subunit. (1988) (0)
- A protocol for characterizing T-cell receptors from human histological specimens and for identifying their antigens. (2006) (0)
- Natalizumab as New Therapeutic Option for Multiple Sclerosis (2008) (0)
- Tissue-resident CD8+ memory T cells in multiple sclerosis. (2020) (0)
- Correction: Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (0)
- Myasthenia gravis measurement of anti achr antibodies using achr from the cell line te671 (1991) (0)
- Risk Factors for Relapses After Switching From Natalizumab To Fingolimod (P7.241) (2014) (0)
- Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (0)
- ENS Communications (2001) (0)
- Eleventh meeting of The European Neurological Society21–25 April, 2001, Paris, France (2001) (0)
- Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair (2022) (0)
- Contactin-2/TAG-1 directed autoimmunity is identified in MS patients and mediates gray matter pathology in EAE (2008) (0)
- Exome Array GWAS in 10,000 Germans Identifies Association between MUC22 and Multiple Sclerosis (2015) (0)
- Somatic hypermutation of intrathecal IgM-producing B cells in multiple sclerosis patients (2012) (0)
- Neurofascin-specific Autoantibodies Mediate Axonal Injury in Inflammatory Demyelinating Diseases of the Central Nervous System (2007) (0)
- [Current therapy of multiple sclerosis: mitoxantrone]. (1994) (0)
- Identification of circulating MOG-specific B cells in patients with MOG antibodies (2020) (0)
- Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies (2021) (0)
- Concurrent TNFRSF 1 A R 92 Q and pyrin E 230 K mutations in a child with multiple sclerosis (2010) (0)
- [Immunotherapy of multiple sclerosis. Consensus and controversies]. (1999) (0)
- [Multiple sclerosis: can therapy delay ongoing disability?]. (2011) (0)
- Secondary cerebrovenous outflow in relation to duration of disease in patients with multiple sclerosis (2012) (0)
- [Neurology. Therapeutic advances through systems research and molecular biology]. (1999) (0)
- [Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis]. (1997) (0)
- Rituximab: eine Therapieoption bei Neuromyelitis optica? (2009) (0)
- Tumor immune therapy targeted against on coneuronal antigens: might this approach induce encephalomyelitis? (2001) (0)
- Polymyositis. (1992) (0)
- [Neurology 2000. From the molecule to the system]. (1999) (0)
- Retromer SortingA Pathogenic Pathway in Late-Onset Alzheimer Disease (2008) (0)
- Cover Picture: Eur. J. Immunol. 8/09 (2009) (0)
- DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis (2019) (0)
- Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement (2015) (0)
- The homeostatic chemokine CCL19 is constitutively expressed in the CNS, up-regulated in multiple sclerosis lesions, and is correlated with intrathecal IgG production (2006) (0)
- Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose (2016) (0)
- Optical coherence tomography (OCT) pattern in myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies positive patients: characterised by severe optic neuritis and subclinical retinal axonal degeneration (2016) (0)
- Astrocytes trigger neurodegeneration through nitric oxide release after TrkB engagement: Implications for multiple sclerosis (2012) (0)
- Effect of early initiation or switch to fingolimod on relapse outcomes in patients with relapsing-remitting multiple sclerosis: Pooled analysis from Phase 3 and Real-World studies (2017) (0)
- ["Fatigue" in multiple sclerosis]. (2000) (0)
- PW02-032 - CNS manifestations and NLRP3/CIAS1 gene mutations (2013) (0)
- Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination (2014) (0)
- Soluble TNFα receptor (p55)-1gG inhibits proliferation of human T-cell lines in vitro. Implications for multiple sclerosis therapy (1995) (0)
- Immune Cells Ligands and Their Receptors on Human Line-Derived Neurotrophic Factor Family Expression and Function of Glial Cell (2005) (0)
- Faculty Opinions recommendation of Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. (2007) (0)
- IN VITRO SELECTION OF RAT AUTOIMMUNE HELPER T‐LYMPHOCYTES SPECIFIC FOR ACETYLCHOLINE RECEPTOR (AChR) (1981) (0)
- Interferontherapie der Multiplen Sklerose (2004) (0)
- clinical implications of basic research Molecular Mimicry in Multiple Sclerosis (2003) (0)
- Maintenance of B cells and plasma cell in the CNS in multiple sclerosis (2008) (0)
- Chapter 38. Cerebral Vasculitis (2008) (0)
- Measurement of anti-acetylcholine receptor antibodies using the cell line TE671 (1991) (0)
- Activation in Autoimmunity Released by ADAM10 and Reflects B Cell The Immunoregulator Soluble TACI Is (2014) (0)
- Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS) (2350) (2020) (0)
- Trans-species activation of a myelin basic protein (MBP)-specific human T cell clone using APC from MHC-compatible rhesus monkeys (1994) (0)
- Reply (2006) (0)
- [Myasthenia gravis. Prototype of an anti-receptor autoaggression disease (author's transl)]. (1981) (0)
- Abstracts of the Symposia (2006) (0)
- [Current therapy of multiple sclerosis. Oral tolerance induction to myelin antigens]. (1993) (0)
- Review of Novel Immunotherapeutic Strategies for MS (2007) (0)
- [Betaferon and therapy of multiple sclerosis--present and future]. (2001) (0)
- [Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids]. (1992) (0)
- Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study (2019) (0)
- [Bone marrow and stem cell transplantation in multiple sclerosis?]. (1999) (0)
- Fingolimod induces neuroprotective factors in human astrocytes (2015) (0)
- Subclinical concordance rate in monozygotic twins clinically discordant for multiple sclerosis. (2016) (0)
- Perforin expression in polymyositis and other inflammatory muscle diseases (1994) (0)
- Identi cation and temporal stability of conformational epitopes of autoantibodies against Myelin Oligodendrocyte Glycoprotein recognized by patients with di erent in ammatory central nervous system diseases (2014) (0)
- New tools for investigating the immunopathogenesis of MS: Principles and applications (2008) (0)
- [Analysis of surface markers on cerebrospinal fluid-producing cells. Contribution to the differential diagnosis of intrathecal lymphomas]. (1984) (0)
- Altered grey matter networks in young patients with MS at genetic risk for Alzheimer's disease (2017) (0)
- [Multiple sclerosis. Therapeutic nihilism is the wrong approach here]. (2002) (0)
- T cell transformation byHerpesvirus saimiri: Immortalized cells from human and rhesus monkey share essential properties (2007) (0)
- T cell receptor immunotherapy in multiple sclerosis? Human T cell lines recognizing peptide analogs of T cell receptor β chains from MBP specific autologous T cell clones (1991) (0)
- Twin study reveals non-heritable immune perturbations in multiple sclerosis (2022) (0)
- Anti-CD20 B-Cell Depletion Increases the Frequency of Regulatory T Cells, but Enhances Monocyte Reactivity in Multiple Sclerosis and Neuromyelitis Optica (2011) (0)
- Soluble BCMA is shed from B cells by gamma-secretase, functions as APRIL-specific decoy and reflects intrathecal Ig-production in multiple sclerosis (2014) (0)
- IN24-TU-01 Immunological and neurobiological interactions in multiple sclerosis (2009) (0)
- Model of myasthenia gravis using human thymus tissue transplanted into SCID mice (1991) (0)
- Nervous System Diseases Central Patients with Different Inflammatory Oligodendrocyte Glycoprotein Recognized by Conformational Epitopes on Myelin Distinction and Temporal Stability of (2013) (0)
- Molecular characterization of paired immunoglobulin heavy and light chains of clonally expanded antibodies in the presence of a strong polyclonal background (2017) (0)
- MRI, Big Data, and Artificial Intelligence (2021) (0)
- [Does interferon beta slow the progression of multiple sclerosis? Long-term effect of IFN-β on progression of physical disability is still not proven]. (2012) (0)
- T cell receptors of “mucosal-associated invariant T” cells in multiple sclerosis brain lesions (2014) (0)
- Principles of Immunomodulatory Therapy (1994) (0)
- 010 Radio-immunoprecipitation-assay for acetylcholine-receptor antibodies using cell line TE671 (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Reinhard Hohlfeld?
Reinhard Hohlfeld is affiliated with the following schools: